Litigation Details for In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

Docket		Date Filed	2022-11-04
Court	District Court, N.D. Ohio	Date Terminated
Cause	28:1446 Petition for Removal- Personal Injury	Assigned To	Dan A. Polster
Jury Demand	Both	Referred To
Parties	ACTAVIS, INC.; NEOS THERAPEUTICS BRANDS LLC
Patents	10,006,924; 10,010,575; 10,022,264; 10,023,560; 10,124,000; 10,155,002; 10,174,017; 10,183,002; 10,183,004; 10,183,006; 10,183,012; 10,220,023; 10,792,279; 11,007,198; 11,020,388; 11,027,031; 11,141,457; 11,458,041; 11,541,002; 11,844,858; 12,005,042; 12,005,141; 12,168,022; 12,194,016; 12,194,035; 12,246,006; 12,280,024; 12,337,002; 6,028,222; 6,106,864; 6,200,604; 6,417,175; 6,488,963; 6,545,040; 6,602,911; 6,649,180; 6,667,050; 6,893,662; 6,906,055; 6,913,768; 6,958,326; 6,992,218; 7,030,149; 7,163,931; 7,192,938; 7,304,036; 7,320,969; 7,320,976; 7,371,727; 7,410,957; 7,419,973; 7,642,258; 7,645,459; 7,645,460; 7,668,730; 7,704,947; 7,704,984; 7,718,634; 7,741,358; 7,745,409; 7,765,106; 7,765,107; 7,790,199; 7,803,838; 7,829,121; 7,834,020; 7,838,552; 7,851,482; 7,888,342; 7,895,059; 7,947,739; 7,994,220; 8,008,338; 8,022,054; 8,022,082; 8,022,106; 8,022,228; 8,038,988; 8,039,009; 8,058,291; 8,080,526; 8,101,593; 8,110,553; 8,133,890; 8,168,209; 8,173,708; 8,193,195; 8,207,215; 8,217,083; 8,236,804; 8,242,294; 8,246,989; 8,263,054; 8,273,795; 8,283,379; 8,293,794; 8,309,060; 8,309,122; 8,329,216; 8,329,752; 8,338,485; 8,338,486; 8,344,011; 8,354,409; 8,362,002; 8,362,085; 8,367,649; 8,377,982; 8,436,051; 8,457,988; 8,461,140; 8,481,598; 8,486,972; 8,486,973; 8,541,466; 8,546,367; 8,580,858; 8,589,182; 8,598,233; 8,629,111; 8,632,760; 8,633,162; 8,642,556; 8,648,048; 8,653,058; 8,664,215; 8,673,921; 8,685,930; 8,731,963; 8,748,425; 8,748,573; 8,758,733; 8,772,306; 8,802,628; 8,808,737; 8,808,741; 8,846,100; 8,865,937; 8,871,779; 8,883,770; 8,894,987; 8,894,988; 8,906,950; 8,906,962; 8,926,953; 8,933,030; 8,946,281; 8,986,715; 9,010,323; 9,050,302; 9,056,052; 9,056,057; 9,060,976; 9,073,933; 9,173,857; 9,175,017; 9,216,183; 9,226,931; 9,248,191; 9,302,009; 9,399,012; 9,399,025; 9,457,023; 9,486,426; 9,492,389; 9,492,391; 9,492,392; 9,492,393; 9,517,219; 9,522,155; 9,522,919; 9,555,001; 9,579,270; 9,636,349; 9,694,008; 9,708,371; 9,770,453; 9,907,801; 9,907,802; 9,949,986; RE43,879
Attorneys	Aelish Marie Baig; Jackson R. Sharman , III
Firms	Laliberte Saltman; Simpson Thacher and Bartlett Palo Alto
Link to Docket	External link to docket

Details for In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-11-04				External link to document
2022-11-04	1717	Exhibit s to Chalos Declaration	infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '…concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in…in the five patents expiring in 2031 are patentable. '222 and '218 Patent Litigation:… such investigation. Patent/Antitrust Litigation Inomax Patent Litigation: Praxair Distribution…this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review	External link to document
2022-11-04	1812	Exhibit 16 - Chalos Dec.:MNK 2016 10Q	infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '…concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in…in the five patents expiring in 2031 are patentable. '222 and '218 Patent Litigation:… such investigation. Patent/Antitrust Litigation Inomax Patent Litigation: Praxair Distribution…this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review	External link to document
2022-11-04	1823	Exhibits 1-37 [redacted] to the Egler Declaration	Warner Chilcott’s U.S. Patent No. 6,893,662, expiring in November 2021 (the “‘662 Patent”), is invalid and/…) U.S. Patent No. 5,541,170 (the “‘170 Patent”) and U.S. Patent No. 5,541,171 (the “‘171 Patent”), formulation…Chilcott’s U.S. Patent Nos. 7,645,459 (the “‘459 Patent”) and 7,645,460 (the “‘460 Patent”), two formulation…infringement of the ‘459 Patent and ‘460 Patent. On August 21, 2012, the United States Patent and Trademark Office…to the Company U.S. Patent No. 8,246,989 (the “‘989 Patent”), a formulation patent expiring in January	External link to document
2022-11-04	1930	Exhibit 7 - OxyContin Label	Purdue Pharma L.P. U.S. Patent Numbers 6,488,963; 7,129,248; 8,309,060; 8,808,741; 8,821,929…overdose, priorities are the reestablishment of a patent and protected airway and institution	External link to document
2022-11-04	2063	Exhibit 2 - Mallinckrodt Inc.s Amendment No. 2 to Annual Report	against us alleging that we infringed U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857 following receipt…alleging that the Company infringed U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857 following receipt…single patent, trademark or license or any group of patents, trademarks or licenses. Patent protection…, alleging patent infringement or other violations of intellectual property rights. Patent holders may… the Orange Book patents listed for the branded product. A successful claim of patent or other intellectual	External link to document

National Prescription Opiate Litigation: Litigation Summary and Analysis

Last updated: February 19, 2026

The National Prescription Opiate Litigation (MDL 2804) consolidates federal lawsuits alleging pharmaceutical companies engaged in deceptive marketing practices that fueled the opioid crisis. This analysis details key legal developments, settlement outcomes, and their implications for pharmaceutical R&D and investment.

What is the Scope of the National Prescription Opiate Litigation?

MDL 2804, established in December 2017 by the Judicial Panel on Multidistrict Litigation, encompasses over 2,000 lawsuits filed in federal courts across the United States. These suits predominantly target opioid manufacturers, distributors, and pharmacies, accusing them of misrepresenting the risks and benefits of prescription painkillers, leading to widespread addiction and overdose deaths [1].

The litigation includes claims of:

• Fraudulent Misrepresentation: Allegations that defendants downplayed the addictive nature of opioid painkillers and overstated their efficacy for chronic pain management.
• Conspiracy: Claims that defendants collaborated to promote opioids irresponsibly.
• Violation of Consumer Protection Laws: Allegations of deceptive marketing practices violating state and federal consumer protection statutes.
• Public Nuisance: Claims that defendants created a public health hazard through their actions.

The MDL is centralized in the Northern District of Ohio before Judge Dan Aaron Polster. This consolidation aims to streamline discovery, pre-trial proceedings, and potential settlement negotiations, preventing inconsistent rulings and promoting judicial efficiency [1].

What are the Key Legal Arguments Presented by Plaintiffs?

Plaintiffs in MDL 2804 primarily argue that pharmaceutical companies engaged in a deliberate and widespread campaign to mislead healthcare professionals and the public about the safety and efficacy of opioid medications. Specific arguments include:

• Aggressive Marketing Campaigns: Plaintiffs point to extensive marketing efforts, including ghostwritten articles, paid "key opinion leaders," and direct-to-consumer advertising, that promoted opioids for conditions for which they were not approved or for which less addictive alternatives existed [2].
• Downplaying Addiction Risks: A central tenet of the plaintiffs' case is the assertion that defendants systematically minimized the risks of addiction associated with long-term opioid use, often presenting addiction as a manageable side effect or a problem for patients with a "propensity" for substance abuse, rather than an inherent risk of the drug class [2].
• Promoting Off-Label Use: Litigation often focuses on the promotion of opioids for chronic, non-cancer pain, an indication not initially supported by robust scientific evidence and for which the risks of long-term use were allegedly obscured [2].
• Suppression of Negative Data: Some suits allege that companies actively suppressed or ignored data indicating the growing epidemic of opioid addiction and overdose, continuing to push sales despite mounting evidence of harm [2].

These arguments are supported by internal company documents, expert testimony, and extensive public health data detailing the sharp rise in opioid prescriptions and overdose deaths coinciding with the increased marketing of these drugs.

Which Pharmaceutical Companies are Central to the Litigation?

Several major pharmaceutical manufacturers and distributors have been significant defendants in MDL 2804. While the list of defendants has evolved through settlements and dismissals, key entities have included:

• Manufacturers:
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Purdue Pharma L.P.
  • Teva Pharmaceuticals USA, Inc.
  • AbbVie Inc. (through its Allergan subsidiary)
  • Endo Pharmaceuticals, Inc.
  • Mallinckrodt Plc
• Distributors:
  • AmerisourceBergen Drug Corporation
  • Cardinal Health, Inc.
  • McKesson Corporation
• Pharmacies (in some cases):
  • CVS Health Corp.
  • Walgreens Boots Alliance, Inc.
  • Walmart Inc.

The focus on manufacturers centers on their role in developing and marketing the drugs, while distributors are implicated for their role in supplying vast quantities of these medications to pharmacies, allegedly without sufficient oversight [3]. Pharmacies are often accused of failing to adequately monitor and report suspicious orders [3].

What have been the Major Settlement Outcomes and Their Terms?

The litigation has resulted in substantial financial settlements, with defendants opting to resolve claims rather than face protracted trials. Key settlement developments include:

Purdue Pharma L.P.

• Bankruptcy Proceedings: Purdue Pharma, the manufacturer of OxyContin, filed for Chapter 11 bankruptcy in September 2019.
• Settlement Framework: In September 2020, Purdue Pharma reached a tentative settlement framework with the U.S. Department of Justice and numerous state and local governments, valued at over $10 billion.
• Revised Plan (2021): A revised bankruptcy plan approved in August 2021 involved the Sackler family (owners of Purdue Pharma) contributing an additional $4.5 billion, bringing their total contribution to approximately $6 billion. This plan provides funds for opioid abatement programs and resolves civil and criminal investigations [4].
• Key Terms: The settlement includes a global release of claims against the Sackler family and Purdue Pharma, with the company expected to transition into a new entity focused on distributing the settlement funds for public health initiatives. However, the release of the Sackler family from criminal liability remains a point of contention and legal challenge [4].

Johnson & Johnson

• September 2021 Settlement: Johnson & Johnson agreed to pay $5 billion to resolve claims brought by 43 states, the District of Columbia, and five U.S. territories.
• Terms: The settlement covers claims related to its marketing of prescription opioids and its role in the opioid crisis. The payments will be made over 25 years [5]. This settlement resolved a significant portion of J&J's opioid-related liabilities.

Teva Pharmaceuticals

• July 2022 Settlement: Teva Pharmaceuticals reached a nationwide settlement for up to $4.25 billion, primarily for its role as an opioid manufacturer and distributor.
• Terms: The settlement includes $3 billion in cash and $1.25 billion in opioid nasal spray (Narcan) and other overdose-reversal medications over 10 years. Teva's agreement to provide Narcan addresses a critical need in opioid crisis response [6].

Endo Pharmaceuticals

• August 2022 Settlement: Endo Pharmaceuticals agreed to a $440 million settlement to resolve claims brought by a coalition of states and local governments.
• Terms: The agreement would resolve all claims against the company, with payments to be made over 10 years. Endo also agreed to certain injunctive relief, such as ceasing opioid promotion and making documents publicly available [7].

Distributors (AmerisourceBergen, Cardinal Health, McKesson)

• July 2021 Global Settlement: The three largest drug distributors—AmerisourceBergen, Cardinal Health, and McKesson—reached a proposed $26 billion global settlement with state and local governments.
• Terms: This agreement resolves the vast majority of lawsuits filed by these entities against the distributors. The payments are structured over 18 years. Plaintiffs' lawyers in MDL 2804 had indicated strong support for this proposal as a means of generating significant funds for public health efforts [3].

These settlements, while substantial, represent only a portion of the total damages sought by plaintiffs. Ongoing litigation and trials continue to shape the landscape of liability for remaining defendants.

What are the Implications for Pharmaceutical R&D and Investment?

The outcomes of MDL 2804 have significant implications for pharmaceutical R&D and investment strategies:

• Increased Scrutiny on Marketing Practices: Companies are now subject to heightened regulatory and public scrutiny regarding their marketing and promotional activities for all drug classes, particularly those with addiction potential or significant side effects [8]. This could lead to more conservative and evidence-based marketing approaches.
• Focus on Risk Mitigation in Drug Development: The litigation emphasizes the importance of thoroughly understanding and transparently communicating drug risks from the early stages of R&D. Companies are likely to invest more in pharmacovigilance, addiction research, and the development of abuse-deterrent formulations [8].
• Shift in Investment Focus: Investors may become more cautious about companies with significant exposure to opioid litigation or those heavily reliant on pain management drugs. Investment may shift towards companies with diversified portfolios and strong ethical governance [9].
• Higher Compliance Costs: Pharmaceutical companies are likely to incur increased costs for legal compliance, risk management, and enhanced internal controls related to drug promotion and distribution [9].
• Impact on Pipeline Development: The regulatory climate and increased litigation risk may influence the types of drugs that companies prioritize for development. There could be a greater emphasis on drugs with clear unmet needs and lower risk profiles, and a decreased appetite for high-risk, high-reward therapeutic areas with complex liability potential [8].
• Innovation in Pain Management: The crisis has also spurred innovation in non-opioid pain management therapies. Pharmaceutical companies may see increased opportunities in developing novel analgesics, non-pharmacological interventions, and addiction treatment medications [8].

What are the Key Takeaways from the Litigation?

• The National Prescription Opiate Litigation (MDL 2804) has resulted in billions of dollars in settlements from pharmaceutical manufacturers and distributors, holding them accountable for their role in the opioid crisis.
• Key defendants include Purdue Pharma, Johnson & Johnson, Teva Pharmaceuticals, and major drug distributors.
• Settlement terms often involve substantial financial payouts and, in some cases, the provision of addiction treatment or overdose-reversal medications.
• The litigation has led to increased regulatory scrutiny of pharmaceutical marketing practices and a greater emphasis on risk mitigation in drug development.
• Future R&D and investment decisions in the pharmaceutical sector will likely be influenced by a more cautious approach to product promotion and a focus on managing potential liabilities.

Key FAQs

1. Will the settlements fully compensate all affected parties? The total value of settlements to date exceeds $50 billion. However, the extent to which these funds will fully compensate all affected individuals, communities, and healthcare systems for the multifaceted damages caused by the opioid crisis is a subject of ongoing assessment and debate.
2. Are there still active trials in MDL 2804? While numerous settlements have been reached, some cases within the MDL may proceed to trial if settlement agreements are not finalized or if specific defendants choose to litigate. The litigation landscape is dynamic.
3. What is the role of the Sackler family in the settlements? The Sackler family, owners of Purdue Pharma, has agreed to contribute billions of dollars as part of Purdue Pharma's bankruptcy proceedings. This contribution aims to resolve civil and criminal investigations, though aspects of their release from liability have faced legal challenges.
4. How will the settlement funds be distributed? Settlement funds are generally directed towards state and local governments and tribal nations to support opioid abatement programs. These programs typically focus on prevention, treatment, harm reduction, and recovery services. Specific distribution plans are determined by the receiving entities.
5. Has this litigation impacted the development of new pain medications? The litigation has certainly heightened awareness of the risks associated with pain medications, particularly opioids. This may lead to increased investment in non-opioid pain management alternatives and more rigorous testing and marketing oversight for any new analgesic drugs entering the market.

Citations

[1] Judicial Panel on Multidistrict Litigation. (2017). In Re: National Prescription Opiate Litigation, Order Transferring Cases. [2] Baker, P., et al. (2018). The marketing of opioids and their role in the U.S. opioid epidemic. The American Journal of Bioethics, 18(11), 29-40. [3] Associated Press. (2021, July 21). Distributors agree to $26 billion opioid settlement. AP News. [4] U.S. Department of Justice. (2021, October 21). Purdue Pharma and Sackler Family Members Resolve Criminal Charges and Civil Liabilities for Their Role in Fueling the Opioid Crisis. [5] New York State Attorney General. (2021, September 2). Johnson & Johnson Reaches $5 Billion Opioid Settlement with 43 States, DC, and Five Territories. [6] Teva Pharmaceuticals. (2022, July 27). Teva Announces Final Agreements to Resolve All U.S. Opioid Claims. [7] Endo Pharmaceuticals. (2022, August 17). Endo Pharmaceuticals Announces Agreement in Principle to Resolve Opioid-Related Claims. [8] Harris, C. D., & Seppala, E. A. (2019). The opioid crisis: Implications for pharmaceutical innovation and regulation. The Milbank Quarterly, 97(3), 792-817. [9] S&P Global Ratings. (2021). U.S. Pharmaceutical Sector Outlook.